Home LiteratureArticle Details
PMID: 12477860 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

Journal of virology ·Vol. 77 ·No. 1 ·2003-01-00 ·Pages 560-70

Leavitt M, Park EJ, Sidorov IA, Dimitrov DS, Quinnan GV

Abstract

Efforts to develop a vaccine against human immunodeficiency virus type 1 (HIV-1) are complicated by resistance of virus to neutralization. The neutralization resistance phenotype of HIV-1 has been linked to high infectivity. We studied the mechanisms determining this phenotype using clones of the T-cell-line-adapted (TCLA) MN strain (MN-TCLA) and the neutralization-resistant, primary MN strain (MN-P). Mutations in the amino- and carboxy-terminal halves of gp120 and the carboxy terminus of gp41 contributed to the neutralization resistance, high-infectivity phenotype but depended upon sequences in the leucine zipper (LZ) domain of gp41. Among 23 clones constructed to map the contributing mutations, there was a very strong correlation between infectivity and neutralization resistance (R(2) = 0.81; P < 0.0001). Mutations that distinguished the gp120s of MN-P and MN-TCLA clones were clustered in or near the CD4 and coreceptor binding sites and in regions distant from those binding sites. To test the hypothesis that some of these distant mutations may interact with gp41, we determined which of them contributed to high infectivity and whether those mutations modulated gp120-gp41 association in the context of MN-P LZ sequences. In one clone, six mutations in the amino terminus of gp120, at least four of which clustered closely on the inner domain, modulated infectivity. This clone had a gp120-gp41 association phenotype like MN-P: in comparison to MN-TCLA, spontaneous dissociation was low, and dissociation induced by soluble CD4 binding was high. These results identify a region of the gp120 inner domain that may be a binding site for gp41. Our studies clarify mechanisms of primary virus neutralization resistance.

MeSH Terms
Amino Acid Sequence Binding Sites CD4 Antigens/metabolism HIV Envelope Protein gp120/chemistry,metabolism HIV Envelope Protein gp41/metabolism HIV-1/immunology,pathogenicity Humans Molecular Sequence Data Neutralization Tests Structure-Activity Relationship
Chemicals
CD4 Antigens HIV Envelope Protein gp120 HIV Envelope Protein gp41
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Leavitt Maria
Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA. mleavitt@usuhs.mil
Park Eun Ju
Sidorov Igor A
Dimitrov Dimiter S
Quinnan Gerald V
References (47)
47 references, click to expand
  1. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
    J Virol. 2000 Feb;74(4):1961-72 PMID: 10644369
  2. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  3. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
    Biochemistry. 2001 Feb 13;40(6):1662-70 PMID: 11327825
  4. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    J Virol. 2002 Jan;76(2):644-55 PMID: 11752155
  5. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    J Virol. 2002 Mar;76(6):2683-91 PMID: 11861835
  6. Pathology of equine infectious anemia. Proposed classification of pathological types of disease.
    Cornell Vet. 1970 Jul;60(3):393-449 PMID: 5464752
  7. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.
    Virology. 1987 Jan;156(1):171-6 PMID: 3643678
  8. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
    Science. 1987 Sep 11;237(4820):1351-5 PMID: 3629244
  9. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  10. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
    J Virol. 1998 Jun;72(6):4694-703 PMID: 9573233
  11. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
    J Virol. 1998 Sep;72(9):7099-107 PMID: 9696803
  12. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
    J Virol. 1999 Jun;73(6):5225-30 PMID: 10233993
  13. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.
    J Virol. 1999 Jul;73(7):5707-13 PMID: 10364321
  14. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
    Cell. 1988 Apr 8;53(1):55-67 PMID: 2450679
  15. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  16. Envelope sequences of two new United States HIV-1 isolates.
    Virology. 1988 Jun;164(2):531-6 PMID: 3369091
  17. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.
    Cell. 1988 Jul 1;54(1):57-63 PMID: 2838179
  18. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
    N Engl J Med. 1989 Dec 14;321(24):1621-5 PMID: 2586564
  19. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.
    AIDS Res Hum Retroviruses. 1990 Mar;6(3):341-56 PMID: 1971182
  20. Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1.
    AIDS Res Hum Retroviruses. 1990 Mar;6(3):371-80 PMID: 2187500
  21. Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans.
    J Acquir Immune Defic Syndr. 1990;3(8):810-6 PMID: 2366149
  22. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    J Virol. 1990 Aug;64(8):3779-91 PMID: 2370681
  23. Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
    Science. 1990 Nov 23;250(4984):1139-42 PMID: 2251501
  24. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    J Virol. 1991 Mar;65(3):1133-40 PMID: 1995942
  25. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.
    J Virol. 1991 Apr;65(4):2119-23 PMID: 2002555
  26. The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site.
    J Virol. 1991 May;65(5):2682-5 PMID: 2016774
  27. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    J Virol. 1992 Jan;66(1):235-43 PMID: 1727487
  28. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    J Virol. 1992 Mar;66(3):1823-31 PMID: 1637373
  29. HIV interactions with CD4: a continuum of conformations and consequences.
    Immunol Today. 1992 Jun;13(6):201-6 PMID: 1627247
  30. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
    Virology. 1992 Dec;191(2):732-42 PMID: 1280382
  31. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  32. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
    J Virol. 1993 Aug;67(8):4557-65 PMID: 8331723
  33. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Virology. 1994 Mar;199(2):431-8 PMID: 8122371
  34. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    J Virol. 1994 Sep;68(9):5854-62 PMID: 7520095
  35. Preparation and characterization of human HIV type 1 neutralizing reference sera.
    AIDS Res Hum Retroviruses. 1995 Jul;11(7):783-7 PMID: 7546904
  36. Immune escape and tropism of HIV.
    Trends Microbiol. 1995 Sep;3(9):356-61 PMID: 8520889
  37. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    J Infect Dis. 1996 Jan;173(1):60-7 PMID: 8537683
  38. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
    Science. 1996 Mar 15;271(5255):1582-6 PMID: 8599114
  39. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
    Science. 1996 May 10;272(5263):872-7 PMID: 8629022
  40. Identification of a major co-receptor for primary isolates of HIV-1.
    Nature. 1996 Jun 20;381(6584):661-6 PMID: 8649511
  41. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
    Science. 1996 Jun 28;272(5270):1955-8 PMID: 8658171
  42. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection.
    J Virol. 1996 Aug;70(8):5306-11 PMID: 8764041
  43. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
    J Virol. 1997 Apr;71(4):2779-85 PMID: 9060632
  44. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  45. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  46. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
    J Infect Dis. 1997 Aug;176(2):384-97 PMID: 9237703
  47. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    J Virol. 2000 May;74(9):4183-91 PMID: 10756031
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2003-01-00
Pages
560-70
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC140585
Subset
IM
Grants
NIAID NIH HHS · R01 AI037438 · United States
NIAID NIH HHS · R21 AI037438 · United States
NIAID NIH HHS · AI 37438 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com